NDA 218718 · Millicent Mfg Pr
Femlyv
Ethinyl Estradiol, Norethindrone Acetate · Oral
Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 22, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
501
113 Phase 3, 20 recruiting
FAERS reports
8
7 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive (COC) use. This risk increases with age, particularly in females over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including FEMLYV, are contraindicated in females who are over 35 years of age and smoke [see Contraindications (4) and Warnings & Precautions (5) ]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use FEMLYV ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use ( 4 )
What it is approved for
From the label in effect Sep 3, 2025.
FEMLYV is indicated for use by females of reproductive potential to prevent pregnancy [see Clinical Studies (14) ] . Limitations of Use The efficacy of FEMLYV in females with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. FEMLYV is a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy ( 1 ) Limitations of Use The efficacy in females of reproductive potential with a body mass index of more than 35 kg/m 2 has not been evaluated ( 1 , 8.8 )
Mechanism: CHCs lower the risk of becoming pregnant primarily by suppressing ovulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- FEMLYV · ETHINYL ESTRADIOL 0.02MG; NORETHINDRONE ACETATE 1MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
- Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00413062 · 2,281 participants · Start Jun 2006 · Primary completion Aug 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00511199 · 2,152 participants · Start May 1, 2006 · Primary completion Apr 1, 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery SystemPivotal-lookingCompleted
Agile TherapeuticsIndustry
NCT02158572 · 2,032 participants · Start Aug 2014 · Primary completion Nov 2016
Drug: AG200-15 · For: Healthy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- breast cancer metastatic2
- abdominal pain1
- abnormal behaviour1
- breast cancer1
- contralateral breast cancer1
- dermatitis allergic1
- dyspnoea1
- endometrial hyperplasia1
- energy increased1
- mouth ulceration1
- oestradiol increased1
- palpitations1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2010 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2025 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, et al. · Int J Gynaecol Obstet 2018 · Meta-Analysis, Systematic Review
- Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
Lin S, Ionescu A, Maynard-Scott J, et al. · Clin Transl Sci 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study.
Kobayashi T, Hirayama M, Nogami M, et al. · Clin Appl Thromb Hemost 2024 · Randomized Controlled Trial, Multicenter Study
- The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy.
Grimmer SF, Back DJ, Orme ML, et al. · Contraception 1986 · Clinical Trial, Randomized Controlled Trial
- Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Millicent Mfg Pr
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.